Identification

Name
Clonazepam
Accession Number
DB01068  (APRD00054)
Type
Small Molecule
Groups
Approved, Illicit
Description

An anticonvulsant used for several types of seizures, including myotonic or atonic seizures, photosensitive epilepsy, and absence seizures, although tolerance may develop. It is seldom effective in generalized tonic-clonic or partial seizures. The mechanism of action appears to involve the enhancement of gamma-aminobutyric acid receptor responses. [PubChem]

Structure
Thumb
Synonyms
  • 1,3-dihydro-7-Nitro-5-(2-chlorophenyl)-2H-1,4.benzodiazepin-2-one
  • 5-(2-Chloro-phenyl)-7-nitro-1,3-dihydro-benzo[e][1,4]diazepin-2-one
  • 5-(2-Chlorophenyl)-7-nitro-1H-benzo[e][1,4]diazepin-2(3H)-one
  • 5-(O-Chlorophenyl)-7-nitro-1,3-dihydro-2H-1,4-benzodiazepin-2-one
  • CLONAZEPAM
  • Clonazepamum
External IDs
RO 5-4023 / RO-5-4023
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Accel-clonazepamTablet1.0 mgOralAccel Pharma IncNot applicableNot applicableCanada
Accel-clonazepamTablet2.0 mgOralAccel Pharma IncNot applicableNot applicableCanada
Accel-clonazepamTablet0.5 mgOralAccel Pharma IncNot applicableNot applicableCanada
ClonapamTablet0.5 mgOralValeant Canada Lp Valeant Canada S.E.C.1997-01-31Not applicableCanada
ClonapamTablet1.0 mgOralValeant Canada Lp Valeant Canada S.E.C.1997-01-31Not applicableCanada
ClonapamTablet2.0 mgOralValeant Canada Lp Valeant Canada S.E.C.1997-02-28Not applicableCanada
ClonazepamTablet1 mgOralMeliapharm Inc2010-10-202014-06-25Canada
ClonazepamTablet0.25 mgOralSivem Pharmaceuticals Ulc2015-07-09Not applicableCanada
ClonazepamTablet0.5 mgOralSivem Pharmaceuticals Ulc2015-07-09Not applicableCanada
ClonazepamTablet1 mgOralSivem Pharmaceuticals Ulc2015-07-09Not applicableCanada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-clonazepam - Tab 0.5mgTablet.5 mgOralApotex Corporation1995-12-31Not applicableCanada
Apo-clonazepam - Tab 2mgTablet2 mgOralApotex Corporation1995-12-31Not applicableCanada
ClonazepamTablet.5 mg/1OralCardinal Health2007-08-01Not applicableUs
ClonazepamTablet, orally disintegrating1 mg/1OralPar Pharmaceutical2005-08-05Not applicableUs
ClonazepamTablet1 mg/1OralAidarex Pharmaceuticals LLC2006-06-28Not applicableUs
ClonazepamTablet.5 mg/1OralPhysicians Total Care, Inc.2005-05-16Not applicableUs
ClonazepamTablet1 mg/1OralA S Medication Solutions2006-06-282017-06-20Us00603 2949 28 nlmimage10 be155f1a
ClonazepamTablet2 mg/1OralRemedy Repack2015-02-132017-03-14Us
ClonazepamTablet.5 mg/1OralRemedy Repack2010-02-04Not applicableUs
ClonazepamTablet, orally disintegrating2 mg/1OralSun Pharmaceutical Industries Limited2017-03-29Not applicableUs
Unapproved/Other Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
ClonazepamTablet1 mg/1OralNu Care Pharmaceuticals,inc.2011-06-03Not applicableUs
International/Other Brands
Antelepsin (AWD) / Iktorivil (Roche) / Rivotril (Roche)
Categories
UNII
5PE9FDE8GB
CAS number
1622-61-3
Weight
Average: 315.711
Monoisotopic: 315.041068908
Chemical Formula
C15H10ClN3O3
InChI Key
DGBIGWXXNGSACT-UHFFFAOYSA-N
InChI
InChI=1S/C15H10ClN3O3/c16-12-4-2-1-3-10(12)15-11-7-9(19(21)22)5-6-13(11)18-14(20)8-17-15/h1-7H,8H2,(H,18,20)
IUPAC Name
5-(2-chlorophenyl)-7-nitro-2,3-dihydro-1H-1,4-benzodiazepin-2-one
SMILES
[O-][N+](=O)C1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1

Pharmacology

Indication

Clonazepam is used as an anticonvulsant in the treatment of the Lennox-Gastaut syndrome (petit mal variant), akinetic and myoclonic seizures. It can also be used for the treatment of panic disorders.

Structured Indications
Pharmacodynamics

Clonazepam, a benzodiazepine, is used primarily as an anticonvulsant in the treatment of absence seizures, petit mal variant seizures (Lennox-Gastaut syndrome), akinetic and myoclonic seizures, and nocturnal myoclonus. It enhances the activity of gamma aminobutyric acid (GABA), which is a major inhibitory neurotransmitter in the central nervous system. In animals, convulsions are antagonized occurs following administration of clonazepam. In humans, clonazepam suppresses the spike and wave discharge in absence seizures (petit mal) and decreases the frequency, amplitude, duration, and spread of discharge in minor motor seizures.

Mechanism of action

Allosteric interactions between central benzodiazepine receptors and gamma-aminobutyric acid (GABA) receptors potentiate the effects of GABA. As GABA is an inhibitory neurotransmitter, this results in increased inhibition of the ascending reticular activating system. Benzodiazepines, in this way, block the cortical and limbic arousal that occurs following stimulation of the reticular pathways.

TargetActionsOrganism
AGABA-A receptor (anion channel)
positive allosteric modulator
Human
UTranslocator protein
other/unknown
Human
UNuclear receptor subfamily 1 group I member 2
partial agonist
Human
Absorption

Clonazepam is rapidly and completely absorbed after oral administration. The absolute bioavailability of clonazepam is about 90%. Cmax, oral administration = 1 -4 hours.

Volume of distribution
Not Available
Protein binding

85% bound to plasma proteins.

Metabolism

Hepatic (cytochrome P450, including CYP3A). Biotransformation occurs mainly by reduction of the 7-nitro group to the 4-amino derivative. This derivative can be acetylated, hydroxylated, and glucuronidated.

Route of elimination

Clonazepam is highly metabolized, with less than 2% unchanged clonazepam being excreted in the urine. Metabolites of Klonopin are excreted by the kidneys. Clonazepam also undergoes acetylation via NAT2.

Half life

30-40 hours

Clearance
Not Available
Toxicity

Somnolence, confusion, coma, and diminished reflexes. The most commonly reported adverse event when clonazepam is used for seizure disorders is CNS depression.
LD50, oral, rats = >15000 mg/kg.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Clonazepam.Experimental
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Clonazepam.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Clonazepam.Approved
AdipiplonThe risk or severity of adverse effects can be increased when Adipiplon is combined with Clonazepam.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Clonazepam.Approved, Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Clonazepam is combined with Alaproclate.Experimental
AlfaxaloneThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Clonazepam.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Clonazepam.Approved, Illicit
AllopregnanoloneThe risk or severity of adverse effects can be increased when Allopregnanolone is combined with Clonazepam.Investigational
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Clonazepam.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Alphaprodine is combined with Clonazepam.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Clonazepam.Approved, Illicit, Investigational
Ambroxol acefyllinateThe therapeutic efficacy of Clonazepam can be decreased when used in combination with Ambroxol acefyllinate.Experimental, Investigational
AminophyllineThe therapeutic efficacy of Clonazepam can be decreased when used in combination with Aminophylline.Approved
AmiodaroneThe metabolism of Clonazepam can be decreased when combined with Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Amisulpride is combined with Clonazepam.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Clonazepam.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Clonazepam.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Clonazepam.Approved
AmperozideThe risk or severity of adverse effects can be increased when Amperozide is combined with Clonazepam.Experimental
AprepitantThe serum concentration of Clonazepam can be increased when it is combined with Aprepitant.Approved, Investigational
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Clonazepam.Approved, Investigational
ArticaineThe risk or severity of adverse effects can be increased when Articaine is combined with Clonazepam.Approved
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Clonazepam.Approved
AtazanavirThe metabolism of Clonazepam can be decreased when combined with Atazanavir.Approved, Investigational
AtomoxetineThe metabolism of Clonazepam can be decreased when combined with Atomoxetine.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Azaperone is combined with Clonazepam.Investigational, Vet Approved
AzelastineClonazepam may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Clonazepam.Approved
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Clonazepam.Illicit
BenperidolThe risk or severity of adverse effects can be increased when Benperidol is combined with Clonazepam.Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Clonazepam.Approved
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Clonazepam.Approved
BoceprevirThe metabolism of Clonazepam can be decreased when combined with Boceprevir.Approved, Withdrawn
BortezomibThe metabolism of Clonazepam can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Clonazepam can be decreased when it is combined with Bosentan.Approved, Investigational
BrexpiprazoleThe risk or severity of adverse effects can be increased when Clonazepam is combined with Brexpiprazole.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Clonazepam.Approved
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Clonazepam.Approved, Illicit
BromisovalThe risk or severity of adverse effects can be increased when Bromisoval is combined with Clonazepam.Experimental
BromperidolThe risk or severity of adverse effects can be increased when Bromperidol is combined with Clonazepam.Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Clonazepam.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Brotizolam is combined with Clonazepam.Approved, Investigational, Withdrawn
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Clonazepam.Approved, Investigational
BuprenorphineClonazepam may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Clonazepam.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Clonazepam.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Butacaine is combined with Clonazepam.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Clonazepam.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Butamben is combined with Clonazepam.Approved
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Clonazepam.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Clonazepam.Approved, Illicit, Vet Approved
CanertinibThe risk or severity of adverse effects can be increased when Canertinib is combined with Clonazepam.Investigational
CarbamazepineThe metabolism of Clonazepam can be increased when combined with Carbamazepine.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Clonazepam.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Clonazepam.Illicit, Investigational, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Clonazepam.Approved
CeritinibThe serum concentration of Clonazepam can be increased when it is combined with Ceritinib.Approved
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Clonazepam.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Clonazepam.Approved, Illicit, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Clonazepam.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Clonazepam.Approved, Investigational, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Clonazepam.Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Clonazepam is combined with Chlorphenamine.Approved
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Clonazepam.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Clonazepam.Approved, Investigational, Withdrawn
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Clonazepam.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Clonazepam.Approved, Vet Approved
CitalopramThe risk or severity of adverse effects can be increased when Clonazepam is combined with Citalopram.Approved
ClarithromycinThe metabolism of Clonazepam can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Clonazepam can be decreased when combined with Clemastine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Clidinium is combined with Clonazepam.Approved
ClobazamThe risk or severity of adverse effects can be increased when Clobazam is combined with Clonazepam.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when clomethiazole is combined with Clonazepam.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Clonazepam is combined with Clomipramine.Approved, Vet Approved
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Clonazepam.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Clopenthixol is combined with Clonazepam.Experimental
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Clonazepam.Approved, Illicit
ClothiapineThe risk or severity of adverse effects can be increased when Clothiapine is combined with Clonazepam.Experimental
ClotrimazoleThe metabolism of Clonazepam can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe risk or severity of adverse effects can be increased when Clonazepam is combined with Clozapine.Approved
CobicistatThe serum concentration of Clonazepam can be increased when it is combined with Cobicistat.Approved
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Clonazepam.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Clonazepam.Approved, Illicit
ConivaptanThe serum concentration of Clonazepam can be increased when it is combined with Conivaptan.Approved, Investigational
CrizotinibThe metabolism of Clonazepam can be decreased when combined with Crizotinib.Approved
CyclizineThe risk or severity of adverse effects can be increased when Clonazepam is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Clonazepam.Approved
CyclosporineThe metabolism of Clonazepam can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Clonazepam.Approved
DabrafenibThe serum concentration of Clonazepam can be decreased when it is combined with Dabrafenib.Approved
DantroleneThe risk or severity of adverse effects can be increased when Clonazepam is combined with Dantrolene.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Clonazepam.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Clonazepam is combined with Dapoxetine.Investigational
DarunavirThe metabolism of Clonazepam can be decreased when combined with Darunavir.Approved
DasatinibThe serum concentration of Clonazepam can be increased when it is combined with Dasatinib.Approved, Investigational
DeferasiroxThe serum concentration of Clonazepam can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Clonazepam can be decreased when combined with Delavirdine.Approved
DeramciclaneThe risk or severity of adverse effects can be increased when Deramciclane is combined with Clonazepam.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Clonazepam.Approved
DesipramineThe risk or severity of adverse effects can be increased when Clonazepam is combined with Desipramine.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Clonazepam.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Clonazepam is combined with Desvenlafaxine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Detomidine is combined with Clonazepam.Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Clonazepam.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Clonazepam.Approved, Vet Approved
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Clonazepam.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Clonazepam.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Clonazepam.Approved, Investigational
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Clonazepam.Approved, Illicit, Vet Approved
Diethyl etherThe risk or severity of adverse effects can be increased when Diethyl ether is combined with Clonazepam.Experimental
DifenoxinThe risk or severity of adverse effects can be increased when Clonazepam is combined with Difenoxin.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Clonazepam.Approved, Illicit
DihydroergotamineThe metabolism of Clonazepam can be decreased when combined with Dihydroergotamine.Approved
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Clonazepam.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Clonazepam.Experimental, Illicit
DiltiazemThe metabolism of Clonazepam can be decreased when combined with Diltiazem.Approved
DimenhydrinateThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Clonazepam.Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Clonazepam.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Clonazepam.Approved, Illicit
DixyrazineThe risk or severity of adverse effects can be increased when Dixyrazine is combined with Clonazepam.Experimental
DoramectinThe risk or severity of adverse effects can be increased when Doramectin is combined with Clonazepam.Vet Approved
DoxepinThe risk or severity of adverse effects can be increased when Clonazepam is combined with Doxepin.Approved
DoxycyclineThe metabolism of Clonazepam can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Clonazepam.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Clonazepam.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Clonazepam.Approved, Illicit
DronedaroneThe metabolism of Clonazepam can be decreased when combined with Dronedarone.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Clonazepam.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Clonazepam.Experimental, Illicit
DuloxetineThe risk or severity of adverse effects can be increased when Clonazepam is combined with Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Clonazepam.Approved
DyphyllineThe therapeutic efficacy of Clonazepam can be decreased when used in combination with Dyphylline.Approved
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Clonazepam.Experimental, Illicit
EcopipamThe risk or severity of adverse effects can be increased when Ecopipam is combined with Clonazepam.Investigational
EfavirenzThe risk or severity of adverse effects can be increased when Efavirenz is combined with Clonazepam.Approved, Investigational
EltanoloneThe risk or severity of adverse effects can be increased when Eltanolone is combined with Clonazepam.Investigational
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Clonazepam.Approved, Investigational, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Clonazepam.Approved, Investigational
EnzalutamideThe serum concentration of Clonazepam can be decreased when it is combined with Enzalutamide.Approved
ErythromycinThe metabolism of Clonazepam can be decreased when combined with Erythromycin.Approved, Vet Approved
EscitalopramThe risk or severity of adverse effects can be increased when Clonazepam is combined with Escitalopram.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Clonazepam.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Clonazepam.Approved
EthanolClonazepam may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Clonazepam.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Clonazepam.Approved
EthotoinThe risk or severity of adverse effects can be increased when Ethotoin is combined with Clonazepam.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Clonazepam.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Ethyl chloride is combined with Clonazepam.Experimental, Investigational
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Clonazepam.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Clonazepam.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Etidocaine is combined with Clonazepam.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Etifoxine is combined with Clonazepam.Investigational, Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Etizolam is combined with Clonazepam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Clonazepam.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Clonazepam is combined with Etoperidone.Withdrawn
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Clonazepam.Illicit, Vet Approved
EzogabineThe risk or severity of adverse effects can be increased when Clonazepam is combined with Ezogabine.Approved
FelbamateThe risk or severity of adverse effects can be increased when Felbamate is combined with Clonazepam.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Clonazepam.Approved, Illicit, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Clonazepam.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe risk or severity of adverse effects can be increased when Fexofenadine is combined with Clonazepam.Approved
FlibanserinThe risk or severity of adverse effects can be increased when Clonazepam is combined with Flibanserin.Approved
FluanisoneThe risk or severity of adverse effects can be increased when Fluanisone is combined with Clonazepam.Experimental
FluconazoleThe metabolism of Clonazepam can be decreased when combined with Fluconazole.Approved
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Clonazepam.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Clonazepam is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Clonazepam.Approved, Illicit
FluoxetineThe risk or severity of adverse effects can be increased when Clonazepam is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Clonazepam.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Clonazepam.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Clonazepam.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Clonazepam.Approved, Investigational
Fluticasone propionateThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Clonazepam.Approved
FluvoxamineThe metabolism of Clonazepam can be decreased when combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe metabolism of Clonazepam can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Clonazepam can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe serum concentration of Fosphenytoin can be increased when it is combined with Clonazepam.Approved
FospropofolThe risk or severity of adverse effects can be increased when Fospropofol is combined with Clonazepam.Approved, Illicit, Investigational
Fusidic AcidThe serum concentration of Clonazepam can be increased when it is combined with Fusidic Acid.Approved
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Clonazepam.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Clonazepam is combined with Gabapentin Enacarbil.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Clonazepam.Approved, Illicit, Investigational
GepironeThe risk or severity of adverse effects can be increased when Gepirone is combined with Clonazepam.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Clonazepam.Approved, Illicit
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Clonazepam.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Clonazepam.Approved, Illicit, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Clonazepam.Approved
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Clonazepam.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Clonazepam.Approved, Illicit, Investigational
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Clonazepam.Approved
HyaluronidaseThe therapeutic efficacy of Clonazepam can be decreased when used in combination with Hyaluronidase.Approved, Investigational
HydrocodoneClonazepam may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Clonazepam.Approved, Illicit
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Clonazepam.Approved
IdelalisibThe serum concentration of Clonazepam can be increased when it is combined with Idelalisib.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Clonazepam is combined with Iloperidone.Approved
ImatinibThe metabolism of Clonazepam can be decreased when combined with Imatinib.Approved
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Clonazepam.Approved
IndalpineThe risk or severity of adverse effects can be increased when Clonazepam is combined with Indalpine.Investigational, Withdrawn
IndinavirThe metabolism of Clonazepam can be decreased when combined with Indinavir.Approved
IndiplonThe risk or severity of adverse effects can be increased when Indiplon is combined with Clonazepam.Investigational
IsavuconazoniumThe metabolism of Clonazepam can be decreased when combined with Isavuconazonium.Approved, Investigational
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Clonazepam.Approved, Vet Approved
IsradipineThe metabolism of Clonazepam can be decreased when combined with Isradipine.Approved
ItraconazoleThe metabolism of Clonazepam can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Clonazepam can be increased when it is combined with Ivacaftor.Approved
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Clonazepam.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Clonazepam.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Clonazepam.Approved, Investigational
KetoconazoleThe metabolism of Clonazepam can be decreased when combined with Ketoconazole.Approved, Investigational
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Clonazepam.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Clonazepam is combined with Levetiracetam.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Clonazepam.Approved, Investigational
LevocabastineThe risk or severity of adverse effects can be increased when Clonazepam is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Clonazepam is combined with Levocetirizine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Clonazepam is combined with Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Clonazepam.Approved, Investigational
LevomilnacipranThe risk or severity of adverse effects can be increased when Clonazepam is combined with Levomilnacipran.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Clonazepam.Approved
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Clonazepam.Approved, Vet Approved
LithiumThe risk or severity of adverse effects can be increased when Lithium is combined with Clonazepam.Approved
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Clonazepam.Illicit
LopinavirThe metabolism of Clonazepam can be decreased when combined with Lopinavir.Approved
LoprazolamThe risk or severity of adverse effects can be increased when Loprazolam is combined with Clonazepam.Experimental
LoratadineThe risk or severity of adverse effects can be increased when Loratadine is combined with Clonazepam.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Clonazepam.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Lormetazepam is combined with Clonazepam.Approved
LovastatinThe metabolism of Clonazepam can be decreased when combined with Lovastatin.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Clonazepam.Approved
LuliconazoleThe serum concentration of Clonazepam can be increased when it is combined with Luliconazole.Approved
LumacaftorThe metabolism of Clonazepam can be increased when combined with Lumacaftor.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Clonazepam.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Clonazepam.Approved, Vet Approved
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Clonazepam.Approved
MebicarThe risk or severity of adverse effects can be increased when Mebicar is combined with Clonazepam.Experimental
MeclizineThe risk or severity of adverse effects can be increased when Meclizine is combined with Clonazepam.Approved
MedazepamThe risk or severity of adverse effects can be increased when Medazepam is combined with Clonazepam.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Medetomidine is combined with Clonazepam.Vet Approved
MefloquineThe therapeutic efficacy of Clonazepam can be decreased when used in combination with Mefloquine.Approved
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Clonazepam.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Melperone is combined with Clonazepam.Approved, Investigational
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Clonazepam.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Clonazepam.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Meptazinol is combined with Clonazepam.Experimental
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Clonazepam.Approved, Investigational
MetaxaloneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Clonazepam.Approved
MethadoneClonazepam may increase the central nervous system depressant (CNS depressant) activities of Methadone.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Clonazepam.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Clonazepam.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Clonazepam.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Clonazepam.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Clonazepam.Approved
MethotrimeprazineClonazepam may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Clonazepam.Approved, Investigational, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Clonazepam is combined with Methsuximide.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Clonazepam.Experimental
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Clonazepam.Approved
MetyrosineClonazepam may increase the sedative activities of Metyrosine.Approved
MianserinThe therapeutic efficacy of Clonazepam can be decreased when used in combination with Mianserin.Approved, Investigational
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Clonazepam.Approved, Illicit
MifepristoneThe serum concentration of Clonazepam can be increased when it is combined with Mifepristone.Approved, Investigational
MilnacipranThe risk or severity of adverse effects can be increased when Clonazepam is combined with Milnacipran.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Clonazepam.Approved, Investigational
MirtazapineClonazepam may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MitotaneThe serum concentration of Clonazepam can be decreased when it is combined with Mitotane.Approved
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with Clonazepam.Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Clonazepam.Approved, Investigational
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Clonazepam.Approved, Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Clonazepam.Approved
NefazodoneThe metabolism of Clonazepam can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Clonazepam can be decreased when combined with Nelfinavir.Approved
NetupitantThe serum concentration of Clonazepam can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Clonazepam can be increased when combined with Nevirapine.Approved
NilotinibThe metabolism of Clonazepam can be decreased when combined with Nilotinib.Approved, Investigational
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Clonazepam.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Clonazepam.Approved, Vet Approved
NorfluraneThe risk or severity of adverse effects can be increased when Norflurane is combined with Clonazepam.Investigational
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Clonazepam.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Clonazepam.Approved
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Clonazepam.Approved, Investigational
OlaparibThe metabolism of Clonazepam can be decreased when combined with Olaparib.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Clonazepam.Approved
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Clonazepam.Approved
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Clonazepam.Approved, Illicit
OrlistatThe serum concentration of Clonazepam can be decreased when it is combined with Orlistat.Approved, Investigational
OrphenadrineClonazepam may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Osanetant is combined with Clonazepam.Investigational
OsimertinibThe serum concentration of Clonazepam can be increased when it is combined with Osimertinib.Approved
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Clonazepam.Approved
OxethazaineThe risk or severity of adverse effects can be increased when Oxethazaine is combined with Clonazepam.Approved, Investigational
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Clonazepam.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Clonazepam.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Clonazepam.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Clonazepam.Approved, Investigational, Vet Approved
PalbociclibThe serum concentration of Clonazepam can be increased when it is combined with Palbociclib.Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Clonazepam.Approved
ParaldehydeClonazepam may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved, Investigational
ParoxetineThe risk or severity of adverse effects can be increased when Clonazepam is combined with Paroxetine.Approved, Investigational
PenfluridolThe risk or severity of adverse effects can be increased when Penfluridol is combined with Clonazepam.Experimental
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Clonazepam.Approved, Vet Approved
PentobarbitalThe metabolism of Clonazepam can be increased when combined with Pentobarbital.Approved, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Clonazepam.Approved
PerazineThe risk or severity of adverse effects can be increased when Perazine is combined with Clonazepam.Investigational
PerospironeThe risk or severity of adverse effects can be increased when Perospirone is combined with Clonazepam.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Clonazepam.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Clonazepam.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Phenazocine is combined with Clonazepam.Experimental
PhenibutThe risk or severity of adverse effects can be increased when Phenibut is combined with Clonazepam.Experimental
PhenobarbitalThe metabolism of Clonazepam can be increased when combined with Phenobarbital.Approved
PhenoperidineThe risk or severity of adverse effects can be increased when Phenoperidine is combined with Clonazepam.Experimental
PhenoxyethanolThe risk or severity of adverse effects can be increased when Phenoxyethanol is combined with Clonazepam.Approved
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Clonazepam.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Clonazepam.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Clonazepam.Approved, Investigational
PipotiazineThe risk or severity of adverse effects can be increased when Clonazepam is combined with Pipotiazine.Approved, Investigational
PiritramideThe risk or severity of adverse effects can be increased when Piritramide is combined with Clonazepam.Investigational
PizotifenThe risk or severity of adverse effects can be increased when Clonazepam is combined with Pizotifen.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Clonazepam is combined with Pomalidomide.Approved
PosaconazoleThe metabolism of Clonazepam can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PramipexoleClonazepam may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Clonazepam.Approved
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Clonazepam.Approved, Illicit
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Clonazepam.Approved, Illicit, Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Clonazepam.Approved
PrimidoneThe metabolism of Clonazepam can be increased when combined with Primidone.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Clonazepam.Approved, Investigational, Vet Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Clonazepam.Approved, Vet Approved
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Clonazepam.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Clonazepam is combined with Promethazine.Approved
PropanididThe risk or severity of adverse effects can be increased when Propanidid is combined with Clonazepam.Experimental
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Clonazepam.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Clonazepam.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Propoxycaine is combined with Clonazepam.Approved
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Clonazepam.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Proxibarbal is combined with Clonazepam.Experimental
PSD502The risk or severity of adverse effects can be increased when PSD502 is combined with Clonazepam.Investigational
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Clonazepam.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Clonazepam.Approved
QuinisocaineThe risk or severity of adverse effects can be increased when Quinisocaine is combined with Clonazepam.Experimental
RacloprideThe risk or severity of adverse effects can be increased when Raclopride is combined with Clonazepam.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Ramelteon is combined with Clonazepam.Approved, Investigational
RanolazineThe metabolism of Clonazepam can be decreased when combined with Ranolazine.Approved, Investigational
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Clonazepam.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Clonazepam.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Clonazepam.Approved, Investigational
RifabutinThe metabolism of Clonazepam can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Clonazepam can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Clonazepam can be increased when combined with Rifapentine.Approved
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Clonazepam.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Ritanserin is combined with Clonazepam.Investigational
RomifidineThe risk or severity of adverse effects can be increased when Romifidine is combined with Clonazepam.Vet Approved
RopiniroleClonazepam may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Clonazepam.Approved
RotigotineClonazepam may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Clonazepam.Approved
SaquinavirThe metabolism of Clonazepam can be decreased when combined with Saquinavir.Approved, Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Clonazepam.Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Clonazepam.Approved, Vet Approved
SepranoloneThe risk or severity of adverse effects can be increased when Sepranolone is combined with Clonazepam.Investigational
SertindoleThe risk or severity of adverse effects can be increased when Sertindole is combined with Clonazepam.Approved, Investigational, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Clonazepam is combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Clonazepam.Approved, Vet Approved
SildenafilThe metabolism of Clonazepam can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Clonazepam can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Clonazepam can be increased when it is combined with Simeprevir.Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Clonazepam.Approved
St. John's WortThe serum concentration of Clonazepam can be decreased when it is combined with St. John's Wort.Investigational, Nutraceutical
StiripentolThe serum concentration of Clonazepam can be increased when it is combined with Stiripentol.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Clonazepam.Approved, Investigational
SulfisoxazoleThe metabolism of Clonazepam can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Clonazepam.Approved, Investigational
SultoprideThe risk or severity of adverse effects can be increased when Sultopride is combined with Clonazepam.Experimental
SuvorexantClonazepam may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TandospironeThe risk or severity of adverse effects can be increased when Tandospirone is combined with Clonazepam.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Clonazepam.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Clonazepam is combined with Tasimelteon.Approved
TeduglutideThe serum concentration of Clonazepam can be increased when it is combined with Teduglutide.Approved
TelaprevirThe metabolism of Clonazepam can be decreased when combined with Telaprevir.Approved, Withdrawn
TelithromycinThe metabolism of Clonazepam can be decreased when combined with Telithromycin.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Clonazepam.Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Clonazepam is combined with Tetrabenazine.Approved
TetracaineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Clonazepam.Approved, Vet Approved
TetracosactideTetracosactide may increase the hepatotoxic activities of Clonazepam.Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Clonazepam.Investigational
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Clonazepam.Investigational
ThalidomideClonazepam may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
TheophyllineThe therapeutic efficacy of Clonazepam can be decreased when used in combination with Theophylline.Approved
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Clonazepam.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Clonazepam.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Clonazepam.Approved, Withdrawn
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Clonazepam.Approved
TiagabineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Clonazepam.Approved
TiaprideThe risk or severity of adverse effects can be increased when Tiapride is combined with Clonazepam.Approved, Investigational
TiclopidineThe metabolism of Clonazepam can be decreased when combined with Ticlopidine.Approved
TiletamineThe risk or severity of adverse effects can be increased when Tiletamine is combined with Clonazepam.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Tilidine is combined with Clonazepam.Experimental
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Clonazepam.Approved
TocilizumabThe serum concentration of Clonazepam can be decreased when it is combined with Tocilizumab.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Clonazepam.Approved, Withdrawn
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Clonazepam.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Clonazepam.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Clonazepam.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Clonazepam.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Clonazepam.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Clonazepam.Approved
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Tricaine methanesulfonate is combined with Clonazepam.Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Trichloroethylene is combined with Clonazepam.Experimental
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Clonazepam.Approved
TrifluperidolThe risk or severity of adverse effects can be increased when Trifluperidol is combined with Clonazepam.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Clonazepam.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Clonazepam.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Clonazepam.Approved
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Clonazepam.Approved, Investigational
VenlafaxineThe metabolism of Clonazepam can be decreased when combined with Venlafaxine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Veralipride is combined with Clonazepam.Experimental
VerapamilThe metabolism of Clonazepam can be decreased when combined with Verapamil.Approved
VigabatrinVigabatrin may increase the central nervous system depressant (CNS depressant) activities of Clonazepam.Approved
Vinyl etherThe risk or severity of adverse effects can be increased when Vinyl ether is combined with Clonazepam.Experimental
VoriconazoleThe metabolism of Clonazepam can be decreased when combined with Voriconazole.Approved, Investigational
VortioxetineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Clonazepam.Approved
XenonThe risk or severity of adverse effects can be increased when Xenon is combined with Clonazepam.Experimental
XylazineThe risk or severity of adverse effects can be increased when Xylazine is combined with Clonazepam.Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Clonazepam.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Clonazepam is combined with Ziconotide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Clonazepam is combined with Zimelidine.Withdrawn
ZiprasidoneThe metabolism of Clonazepam can be decreased when combined with Ziprasidone.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Zolazepam is combined with Clonazepam.Vet Approved
ZolpidemClonazepam may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Clonazepam.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Clonazepam.Approved
ZotepineThe risk or severity of adverse effects can be increased when Zotepine is combined with Clonazepam.Approved, Investigational
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Clonazepam.Approved, Investigational
Food Interactions
  • Avoid alcohol.
  • Avoid excessive quantities of coffee or tea (Caffeine).
  • Take without regard to meals.

References

Synthesis Reference

Kariss, J. and Newmark, H.L.; US. Patents 3,116,203; December 31, 1963; and 3,123,529; March 3, 1964; both assigned to Hoffmann-LaRoche, Inc. Keller, O., Steiger, N. and Sternbach, L.H.; U S . Patents 3,121,114; February 11, 1964; and 3,203890; August 31, 1965; both assigned to Hoffmann-LaRoche, Inc. Focella, A. and Rachlin, A.I.; U.S. Patent 3,335,181; August 8, 1967; assigned to Hoffmann- LaRoche. Inc.

General References
  1. Dreifuss FE, Penry JK, Rose SW, Kupferberg HJ, Dyken P, Sato S: Serum clonazepam concentrations in children with absence seizures. Neurology. 1975 Mar;25(3):255-8. [PubMed:1089913]
  2. Robertson MD, Drummer OH: Postmortem drug metabolism by bacteria. J Forensic Sci. 1995 May;40(3):382-6. [PubMed:7782744]
  3. Rosen GM, Turner MJ 3rd: Synthesis of spin traps specific for hydroxyl radical. J Med Chem. 1988 Feb;31(2):428-32. [PubMed:2828624]
  4. Rosen GM, Demos HA, Rauckman EJ: Not all aromatic nitro compounds form free radicals. Toxicol Lett. 1984 Aug;22(2):145-52. [PubMed:6089382]
  5. Earley JV, Fryer RI, Ning RY: Quinazolines and 1,4-benzodiazepines. LXXXIX: Haptens useful in benzodiazepine immunoassay development. J Pharm Sci. 1979 Jul;68(7):845-50. [PubMed:458601]
External Links
Human Metabolome Database
HMDB15201
KEGG Drug
D00280
PubChem Compound
2802
PubChem Substance
46507677
ChemSpider
2700
BindingDB
50019213
ChEBI
3756
ChEMBL
CHEMBL452
Therapeutic Targets Database
DAP000259
PharmGKB
PA449050
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Clonazepam
ATC Codes
N03AE01 — Clonazepam
AHFS Codes
  • 28:12.08 — Benzodiazepines
MSDS
Download (74.3 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0CompletedTreatmentBurning Mouth Syndrome1
1CompletedNot AvailablePharmacokinetics1
1CompletedNot AvailableTo Determine Bioequivalence Under Fasting Conditions2
1, 2CompletedBasic SciencePain, Neuropathic1
2CompletedTreatmentEpilepsies1
2CompletedTreatmentREM Sleep Behavior Disorder1
2Not Yet RecruitingTreatmentParkinson's Disease (PD) / REM Sleep Behavior Disorder1
2RecruitingTreatmentCannabis Use Disorders1
2, 3CompletedTreatmentPanic Disorders1
3CompletedTreatmentPain1
3CompletedTreatmentStatus; Epilepticus, Tonic-clonic1
3RecruitingTreatmentEpilepsies / Refractory seizure disorders1
3TerminatedTreatmentAnxiety Disorders / Dementias / Depression / Psychosomatic Disorders / Schizophrenic Disorders1
3Unknown StatusTreatmentEpilepsia Partialis Continua / Epilepsies / Kojewnikov's Epilepsy1
4CompletedTreatmentFear of open spaces / Panic Disorders1
4CompletedTreatmentPost Traumatic Stress Disorder (PTSD)1
4CompletedTreatmentSocial Phobia1
4Not Yet RecruitingTreatmentBurning Mouth Syndrome1
4RecruitingDiagnosticSevere Major Depression Disorder1
4RecruitingTreatmentEpilepsies1
4Unknown StatusTreatmentCardiac Arrest1
4WithdrawnTreatmentSchizoaffective Disorders / Schizophrenic Disorders / Schizophreniform Disorder1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Dosage forms
FormRouteStrength
TabletOral1.0 mg
TabletOral2.0 mg
TabletOral.5 mg
TabletOral.5 mg/1
TabletOral1 mg/1
TabletOral2 mg/1
Tablet, orally disintegratingOral.125 mg/1
Tablet, orally disintegratingOral.25 mg/1
Tablet, orally disintegratingOral.5 mg/1
Tablet, orally disintegratingOral1 mg/1
Tablet, orally disintegratingOral2 mg/1
TabletOral0.5 mg
TabletOral1 mg
TabletOral2 mg
TabletOral0.25 mg
Prices
Unit descriptionCostUnit
Klonopin 2 mg tablet2.85USD tablet
Klonopin 1 mg tablet2.17USD tablet
Klonopin 0.5 mg tablet1.91USD tablet
ClonazePAM ODT 2 mg Dispersible Tablet1.67USD dispersible tablet
ClonazePAM ODT 0.25 mg Dispersible Tablet1.22USD dispersible tablet
ClonazePAM ODT 0.5 mg Dispersible Tablet1.18USD dispersible tablet
ClonazePAM ODT 0.125 mg Dispersible Tablet1.17USD dispersible tablet
ClonazePAM ODT 1 mg Dispersible Tablet1.1USD dispersible tablet
Clonazepam 2 mg tablet0.81USD tablet
Clonazepam 1 mg tablet0.63USD tablet
Clonazepam 0.5 mg tablet0.61USD tablet
Rivotril 2 mg Tablet0.38USD tablet
Rivotril 0.5 mg Tablet0.22USD tablet
Apo-Clonazepam 2 mg Tablet0.21USD tablet
Co Clonazepam 2 mg Tablet0.21USD tablet
Mylan-Clonazepam 2 mg Tablet0.21USD tablet
Novo-Clonazepam 2 mg Tablet0.21USD tablet
Phl-Clonazepam 2 mg Tablet0.21USD tablet
Pms-Clonazepam 2 mg Tablet0.21USD tablet
Ratio-Clonazepam 2 mg Tablet0.21USD tablet
Sandoz Clonazepam 2 mg Tablet0.21USD tablet
Co Clonazepam 1 mg Tablet0.19USD tablet
Phl-Clonazepam 1 mg Tablet0.19USD tablet
Pms-Clonazepam 1 mg Tablet0.19USD tablet
Sandoz Clonazepam 1 mg Tablet0.19USD tablet
Apo-Clonazepam 0.5 mg Tablet0.12USD tablet
Co Clonazepam 0.5 mg Tablet0.12USD tablet
Mylan-Clonazepam 0.5 mg Tablet0.12USD tablet
Novo-Clonazepam 0.5 mg Tablet0.12USD tablet
Phl-Clonazepam 0.5 mg Tablet0.12USD tablet
Phl-Clonazepam-R 0.5 mg Tablet0.12USD tablet
Pms-Clonazepam 0.5 mg Tablet0.12USD tablet
Pms-Clonazepam-R 0.5 mg Tablet0.12USD tablet
Ratio-Clonazepam 0.5 mg Tablet0.12USD tablet
Sandoz Clonazepam 0.5 mg Tablet0.12USD tablet
Pms-Clonazepam 0.25 mg Tablet0.07USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)238-240Kariss, J. and Newmark, H.L.; US. Patents 3,116,203; December 31, 1963; and 3,123,529; March 3, 1964; both assigned to Hoffmann-LaRoche, Inc. Keller, O., Steiger, N. and Sternbach, L.H.; U S . Patents 3,121,114; February 11, 1964; and 3,203890; August 31, 1965; both assigned to Hoffmann-LaRoche, Inc. Focella, A. and Rachlin, A.I.; U.S. Patent 3,335,181; August 8, 1967; assigned to Hoffmann- LaRoche. Inc.
water solubility100 mg/L (at 25 °C)MERCK INDEX (1996)
logP2.41HANSCH,C ET AL. (1995)
Predicted Properties
PropertyValueSource
Water Solubility0.0106 mg/mLALOGPS
logP2.76ALOGPS
logP3.15ChemAxon
logS-4.5ALOGPS
pKa (Strongest Acidic)11.89ChemAxon
pKa (Strongest Basic)1.86ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area87.28 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity84.02 m3·mol-1ChemAxon
Polarizability29.59 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9946
Blood Brain Barrier+0.9718
Caco-2 permeable+0.5313
P-glycoprotein substrateSubstrate0.5594
P-glycoprotein inhibitor INon-inhibitor0.8474
P-glycoprotein inhibitor IINon-inhibitor0.9157
Renal organic cation transporterNon-inhibitor0.8179
CYP450 2C9 substrateNon-substrate0.7777
CYP450 2D6 substrateNon-substrate0.8934
CYP450 3A4 substrateSubstrate0.7295
CYP450 1A2 substrateInhibitor0.7646
CYP450 2C9 inhibitorInhibitor0.5213
CYP450 2D6 inhibitorNon-inhibitor0.8271
CYP450 2C19 inhibitorInhibitor0.7441
CYP450 3A4 inhibitorInhibitor0.5565
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.7255
Ames testNon AMES toxic0.6778
CarcinogenicityNon-carcinogens0.6417
BiodegradationNot ready biodegradable1.0
Rat acute toxicity1.6422 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9821
hERG inhibition (predictor II)Non-inhibitor0.8734
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Mass Spectrum (Electron Ionization)MSsplash10-02a9-2492000000-109e2626e8a128b9e433
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as 1,4-benzodiazepines. These are organic compounds containing a benzene ring fused to a 1,4-azepine.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Benzodiazepines
Sub Class
1,4-benzodiazepines
Direct Parent
1,4-benzodiazepines
Alternative Parents
Nitroaromatic compounds / Chlorobenzenes / Aryl chlorides / Cyclic carboximidic acids / Ketimines / Propargyl-type 1,3-dipolar organic compounds / Organic oxoazanium compounds / Azacyclic compounds / Organopnictogen compounds / Organooxygen compounds
show 4 more
Substituents
1,4-benzodiazepine / Nitroaromatic compound / Chlorobenzene / Halobenzene / Aryl chloride / Aryl halide / Monocyclic benzene moiety / Benzenoid / Cyclic carboximidic acid / Ketimine
show 19 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
monochlorobenzenes, 1,4-benzodiazepinone (CHEBI:3756)

Targets

Kind
Protein group
Organism
Human
Pharmacological action
Yes
Actions
Positive allosteric modulator
General Function
Inhibitory extracellular ligand-gated ion channel activity
Specific Function
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine...

Components:
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456]
Details
2. Translocator protein
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Other/unknown
General Function
Cholesterol binding
Specific Function
Can bind protoporphyrin IX and may play a role in the transport of porphyrins and heme (By similarity). Promotes the transport of cholesterol across mitochondrial membranes and may play a role in l...
Gene Name
TSPO
Uniprot ID
P30536
Uniprot Name
Translocator protein
Molecular Weight
18827.81 Da
References
  1. Carmel I, Fares FA, Leschiner S, Scherubl H, Weisinger G, Gavish M: Peripheral-type benzodiazepine receptors in the regulation of proliferation of MCF-7 human breast carcinoma cell line. Biochem Pharmacol. 1999 Jul 15;58(2):273-8. [PubMed:10423168]
  2. Bono F, Lamarche I, Prabonnaud V, Le Fur G, Herbert JM: Peripheral benzodiazepine receptor agonists exhibit potent antiapoptotic activities. Biochem Biophys Res Commun. 1999 Nov 19;265(2):457-61. [PubMed:10558889]
  3. Bolger GT, Abraham S, Oz N, Weissman BA: Interactions between peripheral-type benzodiazepine receptor ligands and an activator of voltage-operated calcium channels. Can J Physiol Pharmacol. 1990 Jan;68(1):40-5. [PubMed:1691678]
  4. Marano G, Massotti M, Spagnolo A, Carpi A: Enhancement of pharmacologically induced bronchoconstriction by Ro 5-4864. Eur J Pharmacol. 1990 Apr 10;179(1-2):237-40. [PubMed:2364987]
  5. Awad M, Gavish M: Solubilization of peripheral-type benzodiazepine binding sites from cat cerebral cortex. J Neurochem. 1989 Jun;52(6):1880-5. [PubMed:2723642]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Partial agonist
General Function
Zinc ion binding
Specific Function
Nuclear receptor that binds and is activated by variety of endogenous and xenobiotic compounds. Transcription factor that activates the transcription of multiple genes involved in the metabolism an...
Gene Name
NR1I2
Uniprot ID
O75469
Uniprot Name
Nuclear receptor subfamily 1 group I member 2
Molecular Weight
49761.245 Da
References
  1. Creusot N, Kinani S, Balaguer P, Tapie N, LeMenach K, Maillot-Marechal E, Porcher JM, Budzinski H, Ait-Aissa S: Evaluation of an hPXR reporter gene assay for the detection of aquatic emerging pollutants: screening of chemicals and application to water samples. Anal Bioanal Chem. 2010 Jan;396(2):569-83. doi: 10.1007/s00216-009-3310-y. Epub 2009 Nov 29. [PubMed:20024649]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic ...
Gene Name
CYP2E1
Uniprot ID
P05181
Uniprot Name
Cytochrome P450 2E1
Molecular Weight
56848.42 Da
References
  1. Tassaneeyakul W, Birkett DJ, Miners JO: Inhibition of human hepatic cytochrome P4502E1 by azole antifungals, CNS-active drugs and non-steroidal anti-inflammatory agents. Xenobiotica. 1998 Mar;28(3):293-301. [PubMed:9574817]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Arylamine n-acetyltransferase activity
Specific Function
Participates in the detoxification of a plethora of hydrazine and arylamine drugs. Catalyzes the N- or O-acetylation of various arylamine and heterocyclic amine substrates and is able to bioactivat...
Gene Name
NAT2
Uniprot ID
P11245
Uniprot Name
Arylamine N-acetyltransferase 2
Molecular Weight
33542.235 Da
References
  1. Olivera M, Martinez C, Gervasini G, Carrillo JA, Ramos S, Benitez J, Garcia-Martin E, Agundez JA: Effect of common NAT2 variant alleles in the acetylation of the major clonazepam metabolite, 7-aminoclonazepam. Drug Metab Lett. 2007 Jan;1(1):3-5. [PubMed:19356010]
  2. Miller ME, Garland WA, Min BH, Ludwick BT, Ballard RH, Levy RH: Clonazepam acetylation in fast and slow acetylators. Clin Pharmacol Ther. 1981 Sep;30(3):343-7. [PubMed:7273597]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
No
General Function
Toxic substance binding
Specific Function
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloid...
Gene Name
ALB
Uniprot ID
P02768
Uniprot Name
Serum albumin
Molecular Weight
69365.94 Da
References
  1. Pacifici GM, Viani A, Rizzo G, Carrai M, Rane A: Plasma protein binding of clonazepam in hepatic and renal insufficiency and after hemodialysis. Ther Drug Monit. 1987 Dec;9(4):369-73. [PubMed:3424402]

Drug created on June 13, 2005 07:24 / Updated on November 19, 2017 20:34